or wait 15s
China-based Hengrui Pharma has entered into a license agreement with Novo Nordisk for HRS-1596, a phase I-read
Japan’s Chugai Pharmaceutical and InxMed (Hong Kong) have entered into a worldwide license agreement reg
Australia-based Telix Pharmaceuticals has signed a strategic agreement to lead a merger with ITM Isotope Techn
United Immunity, a clinical stage biotechnology company, has raised a total of ¥2.2 billion in private fin
The University of Melbourne has joined the Structural Genomics Consortium (SGC) with the establishment of SGC-
Researchers from Birla Institute of Technology and Science, Pilani (BITS Pilani), India and institutions in Ta
HKSH Medical Group (HKSH) and United Imaging Healthcare (United Imaging) have announced the arrival of Hong Ko
AIMD Inc., a Korean medical technology company specialising in AI-powered emergency care, has announced the gl
Piramal Pharma Solutions (PPS), India-based Contract Development and Manufacturing Organization (CDMO) and par
Novotech, the global full-service clinical research organisation (CRO) and scientific advisory company, has re
Neurology is moving from a history of high-risk failures to a period of unprecedented therapeutic experimentation. For decades, the complexity of the brain, limited understanding of disease biology and the formidable blood-brain barrier (BBB) made central nervous system (CNS) drug development one of pharma’s toughest challenges. That equation is now beginning to shift.
Advances in neurobiology, neuroimmunology, precision medicine and drug-delivery technologies are opening new routes to diseases once considered largely untreatable. Recent approvals have introduced disease-modifying and genetically targeted therapies, while the Phase III pipeline is testing approaches aimed at Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), Dravet syndrome and other neurological disorders.
Behind this momentum is a deeper change: developers are moving beyond managing symptoms towards targeting the biological mechanisms that drive disease. The question now is whether this scientific momentum can finally translate into durable clinical benefit—and make disease modification a repeatable reality in neurology.
For Feedback, please email us at: coo@mmactiv.com
MEDICAL JAPAN 2026
RX Japan Ltd
medical-japan.jp@rxglobal.com https://www.medical-jpn.jp/tokyo/en-gb/visit.htmlMakuhari Messe, Japan
Medical Device Development Expo Osaka 2026 (MEDIX)
RX Japan Ltd
mfg-japan.jp@rxglobal.com https://www.manufacturing-world.jp/tokyo/en-gb/gbs/sales/brcdl.html?em=w-osaka-medix-1-enINTEX Osaka, Osaka, Japan
ADX Brisbane 2026
Australian Dental Industry Association (ADIA)
events@adia.org.au https://www.adxbrisbane.org.au/Brisbane Convention & Exhibition Centre (BCEC)
